immunotherapy

Research in Review
Combination Therapy Improves Efficacy of B-Cell Lymphoma Treatment
03/20/2017
JCP Editors
Combining two treatment strategies for the treatment of B-cell lymphoma may be more effective than either strategy alone, according to a study published in Cell Reports (February 28,...
Combining two treatment strategies for the treatment of B-cell lymphoma may be more effective than either strategy alone, according to a study published in Cell Reports (February 28,...
...
03/20/2017
Journal of Clinical Pathways
Editor's Page
A Look Into the Future: What`s Next for Pathways?
03/15/2017
Health care delivery is always in flux, but treatment advances over the last several years have introduced new variables into the health care continuum that were unthinkable even a decade ago. Researchers, providers,...
Health care delivery is always in flux, but treatment advances over the last several years have introduced new variables into the health care continuum that were unthinkable even a decade ago. Researchers, providers,...
Health...
03/15/2017
Journal of Clinical Pathways
Research in Review
New Biomarker for Relapsed or Refractory MZL Identified
02/27/2017
JCP Editors
Patients with marginal zone lymphoma (MZL) who underwent prior therapy with an anti-CD20 antibody regimen may be treatable with a tyrosine kinase inhibitor approved for other blood cancers, according to research...
Patients with marginal zone lymphoma (MZL) who underwent prior therapy with an anti-CD20 antibody regimen may be treatable with a tyrosine kinase inhibitor approved for other blood cancers, according to research...
...
02/27/2017
Journal of Clinical Pathways
Research in Review
First-Line Pembrolizumab for NSCLC Improves HRQoL Versus Chemotherapy
12/08/2016
JCP Editors
Patients with early stage metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 have improved quality of life with pembrolizumab treatment versus standard of care platinum-containing...
Patients with early stage metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 have improved quality of life with pembrolizumab treatment versus standard of care platinum-containing...
...
12/08/2016
Journal of Clinical Pathways
Research in Review
HC-Based Next-Gen Sequencing Aids Treatment Decisions in Lung Cancer
11/23/2016
JCP Editors
Hybrid capture (HC)-based next-generation sequencing (NGS) can identify targetable oncogenic drivers to improve response rates in patients with lung cancer, according to a study published in the Journal of Thoracic...
Hybrid capture (HC)-based next-generation sequencing (NGS) can identify targetable oncogenic drivers to improve response rates in patients with lung cancer, according to a study published in the Journal of Thoracic...
Hybrid...
11/23/2016
Journal of Clinical Pathways
Quiz
Best Targeted Therapy for Melanoma
11/10/2016
JCP Editors
A study published in JAMA Oncology recently showed that treatment with which of the following drug types was just as effective as BRAF- and MEK-targeted therapies for melanoma and also limited the risk of...
A study published in JAMA Oncology recently showed that treatment with which of the following drug types was just as effective as BRAF- and MEK-targeted therapies for melanoma and also limited the risk of...
A...
11/10/2016
Journal of Clinical Pathways
Research in Review
TKI Shows Promise in Sarcoma Study
11/10/2016
JCP Editors
Tivozanib was well-tolerated and showed promising antitumor activity in patients with soft tissue sarcoma overexpressing vascular endothelial growth factors (VEGF), supporting efforts for further research, according...
Tivozanib was well-tolerated and showed promising antitumor activity in patients with soft tissue sarcoma overexpressing vascular endothelial growth factors (VEGF), supporting efforts for further research, according...
...
11/10/2016
Journal of Clinical Pathways
Research in Review
PD-1 Inhibitors Best Targeted Therapy for Advanced Melanoma
11/08/2016
JCP Editors
A combination of immunotherapy treatments improves survival and lowers the risk of life-threatening events for patients with late-stage melanoma compared with targeted therapy, according to a new JAMA Oncology...
A combination of immunotherapy treatments improves survival and lowers the risk of life-threatening events for patients with late-stage melanoma compared with targeted therapy, according to a new JAMA Oncology...
A...
11/08/2016
Journal of Clinical Pathways
Research in Review
CML Mutations Associated With Treatment Failure
10/18/2016
JCP Editors
Somatic mutations may predict treatment failure with tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML), according to a study published in Blood, the journal of the American Society of...
Somatic mutations may predict treatment failure with tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML), according to a study published in Blood, the journal of the American Society of...
...
10/18/2016
Journal of Clinical Pathways
Research in Review
Nivolumab Superior to Standard Therapy for Recurrent Head and Neck Cancer
10/14/2016
JCP Editors
Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck may benefit more from treatment with nivolumab than standard, single agent therapy, according to results from a trial published in...
Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck may benefit more from treatment with nivolumab than standard, single agent therapy, according to results from a trial published in...
...
10/14/2016
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use